Clinical Study

Repiimune Rpl-002-18

Posted Date: Jul 8, 2020

  • Investigator: Rekha Chaudhary
  • Specialties: Cancer, Oncology, Skin Cancer
  • Type of Study: Drug

The goal of this study is to estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination with RP1 for patients with locally advanced or metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC), as assessed by overall response rate(ORR).


To Be Eligible: Must Have Histologically Confirmed Diagnosis Of Cscc That Is Locally Advanced Or Metastatic, Ecog =1, Life Expectancy >12 Weeks, Po2 = 92% On Room Air, No Active Or Previous Infection Or Illness That Could Impact Study Treatment, No Hypersensitivity To Study Drugs Or Excipients, No Other Malignancy Within 3 Years


Cscc, Cutaneous Squamous Cell Carcinoma

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.